Rezdiffra Dosing: 80mg Then 100mg Titration Schedule

Resmetirom, marketed as Rezdiffra, works by selectively activating thyroid hormone receptor beta (THR-beta) when taken orally, with preferential effects in the liver. The FDA approved resmetirom for treating adults with metabolic dysfunction-associated steatohepatitis (MASH, formerly called NASH) when moderate to advanced fibrosis (F2 or F3) is present, as an adjunct to diet and exercise modifications. Resmetirom is not indicated for fatty liver disease lacking fibrosis, and differs mechanistically from GLP-1 receptor agonists, which are sometimes prescribed off-label for MASH.

The direct answer

For adults aged 30 to 49, resmetirom dosing is identical to the dosing used across the broader adult population studied in the pivotal trial that supported approval: 80 mg once daily with food for about the first 12 weeks, then 100 mg once daily if the patient tolerates it and liver enzymes remain acceptable. There is no published age-band-specific dosing rule, no weight-based calculation, and no routine renal adjustment. The clinically important question for this age group is not "what dose" but "what to monitor and for how long," because MASH in a 35-year-old carries a longer runway toward cirrhosis than the same fibrosis stage discovered at 65, and resmetirom's long-term durability beyond the roughly one-year trial window is not yet established.

What this article can and cannot verify

This draft is undergoing source verification before publication. The efficacy figures widely reported for the pivotal phase 3 trial (commonly cited as NASH resolution in roughly 30% of patients on the 100 mg dose versus roughly 10% on placebo at 52 weeks, with corresponding fibrosis improvement) are consistent with the basis for FDA approval, but the specific citation link for that trial has not been independently confirmed for this draft and should be checked against the primary publication before these numbers are presented as exact figures to readers. Treat percentage figures in this article as directionally accurate pending that check, not as verified to the decimal point.

What is established: the FDA approved a fixed 80 mg to 100 mg titration schedule, food is required for absorption, and liver enzyme monitoring is part of the label. What is plausible but not confirmed here: the precise magnitude of dose-response difference between 80 mg and 100 mg, and any claim about long-term outcomes (liver-related mortality, cirrhosis prevention) beyond the trial's histological endpoints, since those outcomes were not the trial's primary measure. What is not established: dosing or safety data specific to the 30-49 age band as its own subgroup, since trial reporting has not been confirmed to break results out that way.

How the two-step titration works

Every adult starts at 80 mg once daily. After approximately 12 weeks, the dose typically increases to 100 mg once daily, the target maintenance dose for most patients. This run-in period lets a clinician check hepatic tolerance before committing to the full dose. Patients who cannot tolerate 100 mg, most often due to gastrointestinal side effects or liver enzyme elevation, may remain on 80 mg. The label does not describe the 80 mg dose as merely a placeholder; trial data reported meaningful histological benefit at 80 mg as well, just numerically lower than at 100 mg.

A typical prescribing sequence: confirm the MASH diagnosis and fibrosis stage (by biopsy or a validated noninvasive method), check baseline liver enzymes and bilirubin, start 80 mg with food, reassess around week 12, and step up if labs and tolerability allow.

Food is a requirement, not a suggestion

Resmetirom's absorption depends on being taken with food. The prescribing information describes reduced drug exposure in a fasting state, which is the basis for the with-food requirement rather than a general dosing preference. A normal meal is sufficient; the label does not specify an exact fat or calorie threshold. Patients with irregular schedules should pick whichever meal they eat most reliably and take the tablet with that meal every day.

If a dose is missed, the standard approach for once-daily medications with a long half-life is to take the next scheduled dose with food and not double up, but any patient uncertain about a missed dose should confirm the specific instruction with their prescriber rather than assume this generic guidance applies to their situation.

Monitoring before and during treatment

Liver function testing (ALT, AST, total bilirubin) is expected at baseline, during the titration period, and periodically during maintenance, per FDA labeling. The exact interval during long-term maintenance is left to clinical judgment rather than a fixed label requirement; many hepatology practices check labs every three to six months in the first year, but this is a practice pattern, not a mandated schedule.

Because resmetirom acts through a thyroid hormone receptor pathway, some clinicians also monitor thyroid indicators, though this is a matter of individualized judgment rather than a labeled requirement, and should be discussed with the prescribing clinician rather than assumed as standard for every patient.

Signs that warrant urgent contact with the prescriber, not just the next scheduled visit, include jaundice, dark urine, unexplained fatigue, right upper quadrant pain, or nausea combined with a known transaminase elevation. These are the kinds of signs the label associates with drug-induced liver injury risk and are a reason for prompt reassessment rather than waiting.

Why age 30 to 49 matters for the conversation, not the dose

MASH prevalence is rising in younger adults alongside obesity and type 2 diabetes, and fibrosis discovered at 35 has a longer time horizon to progress toward cirrhosis than the same stage discovered later in life, simply because there are more years for the disease to advance. This is a reason for careful long-term planning and monitoring in this age group, not a reason to alter the dose. Before resmetirom's approval, MASH had no FDA-approved pharmacotherapy; management relied on weight loss, pioglitazone, vitamin E, or off-label GLP-1 receptor agonists. Resmetirom does not replace these; it is used alongside diet and exercise, and it has not been shown to eliminate the need for managing coexisting metabolic conditions such as diabetes or dyslipidemia.

Dose adjustments: what the label does and does not say

No dose adjustment is described for mild to moderate renal impairment. Resmetirom is approved only for MASH with fibrosis stages F2-F3; it has not been studied in decompensated cirrhosis (Child-Pugh B or C), and use in that population should be avoided outside a clinical trial or specialist judgment. Data in compensated cirrhosis (Child-Pugh A) are limited. Dosing is flat rather than weight-based, and the label does not describe a required adjustment by sex, race, or ethnicity based on currently available data. None of this substitutes for an individualized decision by the prescribing clinician, particularly for patients with any degree of hepatic impairment.

Drug interactions relevant to this age group

Resmetirom can raise statin exposure through effects on hepatic uptake transporters, so patients on a statin should have that combination monitored for muscle-related symptoms, and some may have their statin dose adjusted, especially since resmetirom itself lowers LDL cholesterol in trial data. This is an individualized decision, not a rule to apply without a clinician.

Resmetirom is not to be used in pregnancy, and women of childbearing potential need effective contraception during treatment. The label does not describe a direct pharmacokinetic interaction with hormonal contraceptives, but any medication metabolized in the liver is worth a specific conversation about contraceptive reliability with the prescribing clinician rather than an assumption either way.

Side effects at standard doses

Diarrhea and nausea are the most commonly reported side effects in trial data, generally mild and clustering in the first several weeks of treatment, with somewhat higher rates at 100 mg than at 80 mg. Discontinuation due to side effects occurred in a minority of patients. Taking the tablet with a full meal rather than a light snack may reduce gastrointestinal symptoms for some patients, though this is practical advice rather than a labeled instruction.

When to expect a response, and when to reassess

Reductions in liver fat on imaging can appear within the first few months of treatment for many patients, and ALT often begins to normalize early as well. The endpoint that matters most for long-term liver outcomes, histological fibrosis improvement, was assessed at 52 weeks in the pivotal trial, and there is no validated blood test that reliably substitutes for that assessment at earlier time points, though noninvasive markers such as ELF scores or elastography are used in practice as interim signals.

Patients who show no improvement in liver fat or fibrosis markers after roughly a year of treatment should have that lack of response discussed directly with their prescriber. Continued use in apparent non-responders beyond the trial's data window has not been established, and lifestyle modification (meaningful weight loss, diet change, exercise) remains part of MASH management regardless of medication.

Clinician-conversation and monitoring framework

This is a structured way to think through the resmetirom treatment course. It distinguishes what the FDA label specifies from what depends on individualized judgment, and it names concrete stop or escalation conditions rather than leaving "monitor closely" undefined.

The boundary this framework is built around: the FDA label defines the dose, the food requirement, and the existence of a monitoring obligation. It does not define the exact interval of long-term monitoring, how to weigh a partial responder at 12 months, or how to sequence resmetirom against other MASH-relevant interventions such as weight-loss therapy. Those decisions belong to the treating clinician working with the individual patient's labs, comorbidities, and preferences.

Common questions

A note on evidence sources for this draft

The precise percentage figures commonly cited for the pivotal MASH trial that supported Rezdiffra's approval are widely reported in secondary sources, but the specific citation for that trial has not been independently verified for this draft and needs confirmation against the primary journal publication before those numbers are published as exact figures. Readers and clinicians who need the current, authoritative label language, including the full boundaries of the approved indication, contraindications, and monitoring requirements, should consult the FDA's official drug information resources directly: Drugs@FDA search tool. This article does not substitute for that label or for an individualized discussion with the prescribing clinician, and it does not provide personal dosing instructions for any specific patient.